SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

SEC Comment Letter 0000000000-24-007555 to Lanvin Group Holdings Ltd (LANV, LANV-WT) (CIK 0001922097) (LANV)

Lanvin Group Holdings Ltd (LANV, LANV-WT) (CIK 0001922097)
Date: July 2, 2024 · CIK: 0001922097 · Accession: 0000000000-24-007555

AI Filing Summary & Sentiment

File numbers found in text: 001-41569

Date
July 2, 2024
Author
Not clearly detected
Form
UPLOAD
Company
Lanvin Group Holdings Ltd (LANV, LANV-WT) (CIK 0001922097)

Letter

July 2, 2024 David Chan Chief Financial Officer Lanvin Group Holdings Ltd 4F, 168 Jiujiang Road Carlowitz & Co, Huangpu District Shanghai, 200001, China Re:Lanvin Group Holdings Ltd Form 20-F for the Year Ended December 31, 2023 Filed April 30, 2024 File No. 001-41569 Dear David Chan: We have limited our review of your filing to the financial statements and related disclosures and have the following comment(s). Please respond to this letter within ten business days by providing the requested information or advise us as soon as possible when you will respond. If you do not believe a comment applies to your facts and circumstances, please tell us why in your response. After reviewing your response to this letter, we may have additional comments. Form 20-F for the Year Ended December 31, 2023 Operating and Financial Review and Prospects Results of Operations, page 78 1.We note your disclosure on page 79 that the "percentage contribution of...sales incentives, rebates and sales discount is zero." Please tell us and revise your disclosures to clarify what this statement means. Non-IFRS Financial Measures Contribution profit and contribution profit margin, page 106 We note your non-IFRS adjustment for "marketing and selling expenses" in the calculation of contribution profit and contribution profit margin on both a consolidated and segment basis. Considering these expenses appear to represent normal and recurring operating expenses necessary to run your business, please tell us how you determined this adjustment was appropriate. If you believe the adjustment is in compliance with non-2.

July 2, 2024 Page 2 GAAP rules, please advise. Refer to Question 100.01 of the Non-GAAP Financial Measures Compliance and Disclosure Interpretations. Financial Statements Consolidated statements of changes in equity, page F-7 3.Please tell us and revise your disclosures to clearly disclose the nature of the items included within the “capital injection from shareholders” line item for each period presented. In doing so, specify where the transactions are classified within your statement of cash flows and clarify if you have presented any items on a net cash basis. As an example, it appears the $40.4 million amount for fiscal 2023 may represent the $65.4 million issuance of shares net of the $25 million repurchase of shares disclosed in the table on page F-63, but it is unclear how these amounts result in no change to total equity on your statement of changes in equity and where the transactions are classified in your statement of cash flows. 8. Revenue, page F-39 4.We note your disclosure that you generate revenue primarily from the sale of products and from fees for royalties and licenses. We further note your disclosure on page F-23 that you recognize revenues from services. Please tell us and revise your disclosures to clarify where the service and royalty and license revenues are classified within the revenue by sales channel table. Also quantify revenues for each product and service pursuant to IFRS 8.32. 28. Other current liabilities, page F-59 5.Please address the following comments related to your "financing fund" arrangement with Meritz Securities Co., Ltd ("Meritz"):

•Clearly summarize for us the nature and business purpose of each material agreement, transaction, and/or financial instrument related to the financing fund. In doing so, clarify why Meritz is separately selling and "immediately thereafter" agreeing to repurchase your shares.

•Clearly summarize how the individual transactions impacted your financial statements, if at all, including the impact on your statements of cash flows and changes in equity. Ensure you address the put rights held by Meritz, the repurchase of the convertible preference share and approximately 5 million ordinary shares for $54.4 million, and the subscription of approximately 19 million shares at a price of $69.5 million.

•Tell us the specific IFRS guidance, where applicable, that supports your accounting treatment for the preceding transactions, particularly regarding the put rights held by Meritz.

July 2, 2024 Page 3 Exhibits 12.1 and 12.2, page 152 6.We note that your Exhibit 12.1 and 12.2 officer certifications exclude the language of paragraph 4(b) and the introductory language in paragraph 4 regarding responsibilities for establishing and maintaining internal control over financial reporting and the associated design objectives for which certification is required. Please amend your filing to include certifications having all of the prescribed language as set forth in paragraph 12 of the "Instructions as to Exhibits" of Form 20-F. In closing, we remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Heather Clark at 202-551-3624 or Andrew Blume at 202-551-3254 with any questions. Sincerely, Division of Corporation Finance Office of Manufacturing

Show Raw Text
July 2, 2024
David Chan
Chief Financial Officer
Lanvin Group Holdings Ltd
4F, 168 Jiujiang Road
Carlowitz & Co, Huangpu District
Shanghai, 200001, China
Re:Lanvin Group Holdings Ltd
Form 20-F for the Year Ended December 31, 2023
Filed April 30, 2024
File No. 001-41569
Dear David Chan:
            We have limited our review of your filing to the financial statements and related
disclosures and have the following comment(s).
            Please respond to this letter within ten business days by providing the requested
information or advise us as soon as possible when you will respond. If you do not believe a
comment applies to your facts and circumstances, please tell us why in your response.
            After reviewing your response to this letter, we may have additional comments.
Form 20-F for the Year Ended December 31, 2023
Operating and Financial Review and Prospects
Results of Operations, page 78
1.We note your disclosure on page 79 that the "percentage contribution of...sales incentives,
rebates and sales discount is zero." Please tell us and revise your disclosures to clarify
what this statement means.
Non-IFRS Financial Measures
Contribution profit and contribution profit margin, page 106
We note your non-IFRS adjustment for "marketing and selling expenses" in the
calculation of contribution profit and contribution profit margin on both a consolidated
and segment basis. Considering these expenses appear to represent normal and recurring
operating expenses necessary to run your business, please tell us how you determined
this adjustment was appropriate. If you believe the adjustment is in compliance with non-2.

July 2, 2024
Page 2
GAAP rules, please advise. Refer to Question 100.01 of the Non-GAAP Financial
Measures Compliance and Disclosure Interpretations.
Financial Statements
Consolidated statements of changes in equity, page F-7
3.Please tell us and revise your disclosures to clearly disclose the nature of the items
included within the “capital injection from shareholders” line item for each period
presented. In doing so, specify where the transactions are classified within your statement
of cash flows and clarify if you have presented any items on a net cash basis. As an
example, it appears the $40.4 million amount for fiscal 2023 may represent the $65.4
million issuance of shares net of the $25 million repurchase of shares disclosed in the
table on page F-63, but it is unclear how these amounts result in no change to total equity
on your statement of changes in equity and where the transactions are classified in your
statement of cash flows.
8. Revenue, page F-39
4.We note your disclosure that you generate revenue primarily from the sale of products and
from fees for royalties and licenses. We further note your disclosure on page F-23 that
you recognize revenues from services. Please tell us and revise your disclosures to clarify
where the service and royalty and license revenues are classified within the revenue by
sales channel table. Also quantify revenues for each product and service pursuant to IFRS
8.32.
28. Other current liabilities, page F-59
5.Please address the following comments related to your "financing fund" arrangement with
Meritz Securities Co., Ltd ("Meritz"):

•Clearly summarize for us the nature and business purpose of each material
agreement, transaction, and/or financial instrument related to the financing fund. In
doing so, clarify why Meritz is separately selling and "immediately thereafter"
agreeing to repurchase your shares.

•Clearly summarize how the individual transactions impacted your financial
statements, if at all, including the impact on your statements of cash flows and
changes in equity.  Ensure you address the put rights held by Meritz, the repurchase
of the convertible preference share and approximately 5 million ordinary shares for
$54.4 million, and the subscription of approximately 19 million shares at a price of
$69.5 million.

•Tell us the specific IFRS guidance, where applicable, that supports your accounting
treatment for the preceding transactions, particularly regarding the put rights held by
Meritz.

July 2, 2024
Page 3
Exhibits 12.1 and 12.2, page 152
6.We note that your Exhibit 12.1 and 12.2 officer certifications exclude the language of
paragraph 4(b) and the introductory language in paragraph 4 regarding responsibilities for
establishing and maintaining internal control over financial reporting and the associated
design objectives for which certification is required. Please amend your filing to include
certifications having all of the prescribed language as set forth in paragraph 12 of the
"Instructions as to Exhibits" of Form 20-F.
            In closing, we remind you that the company and its management are responsible for the
accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or
absence of action by the staff.
            Please contact Heather Clark at 202-551-3624 or Andrew Blume at 202-551-3254 with
any questions.
Sincerely,
Division of Corporation Finance
Office of Manufacturing